相关临床试验
242
41 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
8
3.3%
已完成
54
22.3%
Enrolling By Invitation
4
1.6%
尚未招募
29
12.0%
招募中
79
32.6%
终止
1
0.4%
Unknown
66
27.3%
撤回
1
0.4%
暂无批准数据
- Bio-Thera Solutions' BAT4406F, an ADCC-enhanced anti-CD20 monoclonal antibody, demonstrated statistically significant efficacy in treating neuromyelitis optica spectrum disorder (NMOSD) during interim analysis of its pivotal Phase II/III trial. - The Independent Data Monitoring Committee recommended early termination of the 45-site Chinese trial due to compelling efficacy results that met pre-defined superiority criteria. - Bio-Thera has closed patient enrollment ahead of schedule and will begin preparing regulatory approval submissions to China's NMPA for this rare autoimmune disease affecting optic nerves and spinal cord. - The breakthrough addresses a critical unmet medical need for NMOSD patients, who face devastating outcomes including permanent blindness, paralysis, and progressive disability with limited current treatment options.
- A 43-year-old epilepsy patient with a brain tumor can now communicate and control actions through computer decoding of her thoughts, marking a significant BCI advancement. - NeuroXess and Huashan Hospital collaborated on the project, showcasing the potential of flexible electrode BCI technologies for restoring basic life functions. - Clinical trials in China are expanding, with NeuroXess achieving 71% accuracy in decoding 142 Chinese syllables within seven days of surgery. - Ethical considerations, including data privacy and patient safety, are being emphasized as BCI technology advances toward broader clinical application.
- A Chinese research team has achieved a breakthrough in brain-computer interface (BCI) technology using a domestically developed, invasive flexible BCI system. - The BCI system demonstrated high-precision, real-time movement intention and language decoding in a clinical trial with a brain injury patient. - The patient could convert thoughts into Chinese text with 71% accuracy for 142 common syllables within seven days of training. - This advancement signifies China's progress to world-class standards in BCI, potentially aiding patients with motor and language impairments.
- A crossover randomized controlled trial, DBS-HITS, is investigating deep brain stimulation (DBS) of the hippocampus for treatment-resistant schizophrenia. - The study involves six participants with chronic, treatment-resistant schizophrenia undergoing DBS surgery and subsequent stimulation parameter optimization. - Participants will be randomized to receive either high-frequency stimulation or sham stimulation for three months each, with blinded evaluations. - The primary outcome is the comparison of response rates in PANSS total, positive, and negative scores, with secondary outcomes including cognitive and neuroimaging changes.
